Xencor, Inc.
DOSING OF A BISPECIFIC ANTIBODY THAT BINDS PD1 AND CTLA4
Last updated:
Abstract:
The present invention is directed to methods for treating a solid cancerous cancer through administering a bispecific anti-PD1 x anti-CTLA4 antibody.
Status:
Application
Type:
Utility
Filling date:
27 Mar 2020
Issue date:
18 Mar 2021